We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
-3.24%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+305.76%
AUM
$73.5B
AUM Growth
-$7.73B
(-9.5%)
Cap. Flow
-$10.4B
Cap. Flow
% of AUM
-14.12%
Top 10 Holdings %
Top 10 Hldgs %
24.14%
Holding
2,549
New
227
Increased
861
Reduced
712
Closed
243
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PPL
PPL Corp
PPL
|
+$301M |
| 2 |
Estee Lauder
EL
|
+$252M |
| 3 |
Boeing
BA
|
+$251M |
| 4 |
Kenvue
KVUE
|
+$174M |
| 5 |
Fidelity National Information Services
FIS
|
+$166M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$547M |
| 2 |
Union Pacific
UNP
|
+$459M |
| 3 |
Pinnacle West Capital
PNW
|
+$203M |
| 4 |
Wells Fargo
WFC
|
+$199M |
| 5 |
Bank of America
BAC
|
+$199M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.75% |
| 2 | Healthcare | 13.74% |
| 3 | Financials | 13.36% |
| 4 | Industrials | 11.58% |
| 5 | Consumer Discretionary | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1926
Bank7 Corp
BSVN
$479M
| $13K | ﹤0.01% |
591
| – | – |
|
|
GBIO
1927
DELISTED
Generation Bio
GBIO
| $12K | ﹤0.01% |
325
+17
| +6% | +$805 |
|
1928
Goldman Sachs ActiveBeta International Equity ETF
GSIE
$6.09B
| $12K | ﹤0.01% |
412
| – | – |
|
1929
Cartesian Therapeutics
RNAC
$257M
| $12K | ﹤0.01% |
392
+19
| +5% | +$635 |
|
1930
Bio-Techne
TECH
$11.2B
| $12K | ﹤0.01% |
188
-119
| -39% | -$9.4K |
|
1931
Tenaya Therapeutics
TNYA
$157M
| $12K | ﹤0.01% |
5,027
+232
| +5% | +$971 |
|
1932
Atara Biotherapeutics
ATRA
$74.3M
| $10K | ﹤0.01% |
285
+14
| +5% | +$623 |
|
|
EBTC
1933
DELISTED
Enterprise Bancorp
EBTC
| $10K | ﹤0.01% |
381
| – | – |
|
1934
ImmunityBio
IBRX
$7.76B
| $10K | ﹤0.01% |
6,167
+268
| +5% | +$538 |
|
1935
Lineage Cell Therapeutics
LCTX
$282M
| $10K | ﹤0.01% |
8,837
+457
| +5% | +$622 |
|
1936
Mattel
MAT
$4.21B
| $10K | ﹤0.01% |
+475
| New | +$10.1K |
|
1937
ProKidney
PROK
$337M
| $10K | ﹤0.01% |
2,419
-358
| -13% | -$3.43K |
|
1938
Repligen
RGEN
$9B
| $10K | ﹤0.01% |
68
+3
| +5% | +$490 |
|
1939
iQIYI
IQ
$1.24B
| $9K | ﹤0.01% |
+2,030
| New | +$10.6K |
|
1940
Karooooo
KARO
$1.97B
| $9K | ﹤0.01% |
+470
| New | +$11K |
|
1941
Nkarta
NKTX
$164M
| $9K | ﹤0.01% |
6,635
+268
| +4% | +$508 |
|
1942
Turkcell
TKC
$4.76B
| $9K | ﹤0.01% |
2,107
+1,605
| +320% | +$7.65K |
|
|
GRTS
1943
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $9K | ﹤0.01% |
5,900
+269
| +5% | +$478 |
|
|
CHUY
1944
DELISTED
Chuy's Holdings, Inc. Common Stock
CHUY
| $9K | ﹤0.01% |
268
+40
| +18% | +$1.54K |
|
1945
Conagra Brands
CAG
$7.11B
| $8K | ﹤0.01% |
325
| – | – |
|
1946
DHI Group
DHX
$178M
| $8K | ﹤0.01% |
2,762
-3,685
| -57% | -$13.1K |
|
1947
CGI
GIB
$15.4B
| $8K | ﹤0.01% |
88
| – | – |
|
1948
Lyell Immunopharma
LYEL
$348M
| $8K | ﹤0.01% |
295
+11
| +4% | +$522 |
|
1949
U-Haul Holding Co Series N
UHAL.B
$12.8B
| $8K | ﹤0.01% |
159
+24
| +18% | +$1.3K |
|
1950
Xperi
XPER
$331M
| $8K | ﹤0.01% |
853
| – | – |
|
Similar funds
QCM
Lazard Asset Management's Q3 2023 Portfolio in Review
As of Q3 2023, Lazard Asset Management held 2,549 positions worth $73.5B, down 9.5% from $81.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Lazard Asset Management withdrew a net $10.4B in Q3 2023, closing 243 positions and reducing 712 holdings. Its most notable exit was Littelfuse, an estimated $24.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Lazard Asset Management opened a new position in ScottsMiracle-Gro worth $28.3M.
- Lazard Asset Management's largest Q3 2023 buy was ScottsMiracle-Gro: 548,310 shares worth $28.3M.
- Lazard Asset Management added most to PPL Corp in Q3 2023, an estimated $301M increase.
- Lazard Asset Management's biggest Q3 2023 reduction was Johnson & Johnson, cutting an estimated $547M.
- Lazard Asset Management fully exited Littelfuse in Q3 2023, selling an estimated $24.3M.
- Lazard Asset Management's ten largest holdings make up 24% of its $73.5B portfolio in Q3 2023.
- Lazard Asset Management opened 227 new positions and closed 243 in Q3 2023.
- Lazard Asset Management's portfolio value fell 9.5% quarter-over-quarter to $73.5B.
Based on Lazard Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.